Cargando…

Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study

Background: Triple-negative breast cancer (TNBC) accounts for 12–20% of all breast cancers. Diagnosis of TNBC is sometimes quite difficult based on morphological assessment and immunohistochemistry alone, particularly in the metastatic setting with no prior history of breast cancer. Methods: Molecul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qifeng, Xu, Midie, Sun, Yifeng, Chen, Jinying, Chen, Chengshu, Qian, Chenhui, Chen, Yizuo, Cao, Liyu, Xu, Qinghua, Du, Xiang, Yang, Wentao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513966/ https://www.ncbi.nlm.nih.gov/pubmed/31134153 http://dx.doi.org/10.3389/fonc.2019.00354

Ejemplares similares

Identification and validation of a 44-gene expression signature for the classification of renal cell carcinomas
por: Wang, Qifeng, et al.
Publicado: (2017)

Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study
por: Wang, Qifeng, et al.
Publicado: (2021)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

RUNX2 facilitates aggressiveness and chemoresistance of triple negative breast cancer cells via activating MMP1
por: Si, Wentao, et al.
Publicado: (2022)

Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
por: Ren, Xin-yu, et al.
Publicado: (2021)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
por: Wang, Meng, et al.
Publicado: (2021)

Development and validation of an inflammatory response-related signature in triple negative breast cancer for predicting prognosis and immunotherapy
por: Guo, Yangyang, et al.
Publicado: (2023)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study
por: Kwan, Hiu Yee, et al.
Publicado: (2021)

Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients
por: Sun, Wei, et al.
Publicado: (2022)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023)

Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis
por: Wu, Qiang, et al.
Publicado: (2019)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer
por: Cai, Shuang-Long, et al.
Publicado: (2023)

Oncological Safety of Diagnostic Hysteroscopy for Apparent Early-Stage Type II Endometrial Cancer: A Multicenter Retrospective Cohort Study
por: Zhou, Hui, et al.
Publicado: (2022)

Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary
por: Yu, Bo, et al.
Publicado: (2022)

Correlation Between Mammographic Radiomics Features and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer
por: Yu, Hongwei, et al.
Publicado: (2020)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Prognostic Factor Analysis and Model Construction of Triple-Negative Metaplastic Breast Carcinoma After Surgery
por: Zhu, Keying, et al.
Publicado: (2022)

Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer
por: Li, Meng, et al.
Publicado: (2022)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
por: Xun, Xueqiong, et al.
Publicado: (2022)

Single progesterone receptor-positive phenotype has the similar clinicopathological features and outcome as triple-negative subtype in metastatic breast cancer
por: Luo, Yunbo, et al.
Publicado: (2023)

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
por: Chen, Jigang, et al.
Publicado: (2021)

The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
por: Yan, Hongkai, et al.
Publicado: (2022)

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer
por: Xu, Tao, et al.
Publicado: (2022)

The Clinicopathological Features and Prognosis in Patients With Papillary Renal Cell Carcinoma: A Multicenter Retrospective Study in Chinese Population
por: Hong, Baoan, et al.
Publicado: (2021)

miR-452 Reverses Abnormal Glycosylation Modification of ERα and Estrogen Resistance in TNBC (Triple-Negative Breast Cancer) Through Targeting UGT1A1
por: Li, Yan, et al.
Publicado: (2020)

A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer
por: Qiu, Pengjun, et al.
Publicado: (2022)

Construction and Validation of Nomograms Predicting Survival in Triple-Negative Breast Cancer Patients of Childbearing Age
por: Cui, Xiang, et al.
Publicado: (2021)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
por: Huang, Jia-Yi, et al.
Publicado: (2023)

Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
por: Venetis, Konstantinos, et al.
Publicado: (2021)

LINC00152 Promotes Tumor Progression and Predicts Poor Prognosis by Stabilizing BCL6 From Degradation in the Epithelial Ovarian Cancer
por: Wang, Shunni, et al.
Publicado: (2020)

Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern
por: Li, Ying-Zi, et al.
Publicado: (2022)

90-gene signature assay for tissue origin diagnosis of brain metastases
por: Zheng, Yulong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6eg25ojc5p4ucpltq8rg426hkt